Novel clinical associations between time in range and microangiopathies in people with type 2 diabetes mellitus on hemodialysis.

[1]  E. Huang,et al.  2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. , 2021, Diabetes care.

[2]  E. Huang,et al.  12. Retinopathy, Neuropathy, and Foot Care: Standards of Medical Care in Diabetes-2022. , 2021, Diabetes care.

[3]  P. Rossing.  HbA1c and beyond. , 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  M. Shichiri,et al.  Hemodialysis-Related Glycemic Disarray Proven by Continuous Glucose Monitoring; Glycemic Markers and Hypoglycemia , 2021, Diabetes Care.

[5]  Rieko Kikuchi,et al.  Time in range correlates glycated albumin measured immediately after 2 weeks of continuous glucose monitoring. , 2021, Journal of diabetes and its complications.

[6]  N. Sakane,et al.  Assessment of the accuracy of an intermittent‐scanning continuous glucose monitoring device in patients with type 2 diabetes mellitus undergoing hemodialysis (AIDT2H) study , 2021, Therapeutic apheresis and dialysis.

[7]  H. Koyama,et al.  Association of time in range with hemoglobin A1c, glycated albumin and 1,5‐anhydro‐d‐glucitol , 2020, Journal of diabetes investigation.

[8]  Dongni Zhao,et al.  Association of time in range, as assessed by continuous glucose monitoring, with painful diabetic polyneuropathy , 2020, Journal of diabetes investigation.

[9]  M. Shichiri,et al.  Comparison of accuracy between flash glucose monitoring and continuous glucose monitoring in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2020, Journal of diabetes and its complications.

[10]  K. Khunti,et al.  Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: Evidence-based advances in monitoring and treatment. , 2020, Kidney international.

[11]  I. D. de Boer,et al.  Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease , 2020, BMJ Open Diabetes Research & Care.

[12]  Y. Bao,et al.  Time in range is associated with carotid intima-media thickness in type 2 diabetes. , 2020, Diabetes technology & therapeutics.

[13]  F. Doyle,et al.  Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range , 2019, Diabetes Care.

[14]  Chantal M. Mcmahon,et al.  The Relationship of Hemoglobin A1C to Time-in-Range in Patients with Diabetes. , 2019, Diabetes technology & therapeutics.

[15]  David Rodbard,et al.  The Relationships Between Time in Range, Hyperglycemia Metrics, and HbA1c , 2019, Journal of diabetes science and technology.

[16]  R. Beck,et al.  Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials , 2018, Diabetes Care.

[17]  K. Tuttle,et al.  Diabetic Kidney Disease: Challenges, Progress, and Possibilities. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[18]  Eyal Dassau,et al.  International Consensus on Use of Continuous Glucose Monitoring , 2017, Diabetes Care.

[19]  R. Freeman,et al.  Diabetic Neuropathy: A Position Statement by the American Diabetes Association , 2016, Diabetes Care.

[20]  M. Shichiri,et al.  Distinct biomarker roles for HbA1c and glycated albumin in patients with type 2 diabetes on hemodialysis. , 2016, Journal of diabetes and its complications.

[21]  K. Kalantar-Zadeh,et al.  Haemodialysis-induced hypoglycaemia and glycaemic disarrays , 2015, Nature Reviews Nephrology.

[22]  Xiao-hua Xu,et al.  Blood glucose fluctuations in hemodialysis patients with end stage diabetic nephropathy. , 2015, Journal of diabetes and its complications.

[23]  M. Abe,et al.  Best Practice for Diabetic Patients on Hemodialysis 2012 , 2015, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[24]  L. Tomlinson,et al.  Association Between Glycemia and Mortality in Diabetic Individuals on Renal Replacement Therapy in the U.K. , 2014, Diabetes Care.

[25]  F. Kronenberg,et al.  Glycated hemoglobin and risk of death in diabetic patients treated with hemodialysis: a meta-analysis. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[26]  B. Kestenbaum,et al.  Kidney disease and increased mortality risk in type 2 diabetes. , 2013, Journal of the American Society of Nephrology : JASN.

[27]  K. Kalantar-Zadeh,et al.  Glycemic Control and Cardiovascular Mortality in Hemodialysis Patients With Diabetes , 2012, Diabetes.

[28]  M. Rocco,et al.  Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[29]  M. Leinung,et al.  Benefits of continuous glucose monitor use in clinical practice. , 2010, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[30]  K. Kalantar-Zadeh,et al.  Glycemic Control and Burnt‐Out Diabetes in ESRD , 2010, Seminars in dialysis.

[31]  Frits R Rosendaal,et al.  Cardiovascular and noncardiovascular mortality among patients starting dialysis. , 2009, JAMA.

[32]  S. Hadjadj,et al.  Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[33]  G. Frost,et al.  Assessing Glycemic Control in Maintenance Hemodialysis Patients With Type 2 Diabetes , 2009, Diabetes Care.

[34]  Mark E. Williams,et al.  Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival. , 2006, Kidney international.

[35]  R. Klein,et al.  Implications of the United kingdom prospective diabetes study. , 2003, Diabetes care.

[36]  W. Cefalu,et al.  Long-term glycemic control measurements in diabetic patients receiving hemodialysis. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[37]  J. Vienken,et al.  The Influence of Different Glucose Concentrations in Haemodialysis Solutions on Metabolism and Blood Pressure Stability in Diabetic Patients , 2001, The International journal of artificial organs.

[38]  M. Akmal.  Hemodialysis in diabetic patients. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[39]  I. Macdonald,et al.  Hemodialysis-induced hypoglycemia in diabetic patients. , 2000, Clinical nephrology.